Press release
August 3, 2026
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics, Inc. (SPTX)
Enrollment in Phase 2b BUOY-1 trial of GlyphAllo ™ in major depressive disorder (MDD) is on track with topline data expected in 1H 2027 Phase 1 driving simulation trial of GlyphAllo on track to report topline data in 2H 2026 Following positive data from completed Phase 1 proof-of-concept trial of